Moore, Malcolm J <br/><br/>
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2007 
 - 1960-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.07.9525  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Deoxycytidine--administration & dosage<br/>Double-Blind Method<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>International Agencies<br/>Male<br/>Middle Aged<br/>Pancreatic Neoplasms--drug therapy<br/>Placebos<br/>Prognosis<br/>Quinazolines--administration & dosage<br/>Survival Rate<br/>Treatment Outcome<br/>Gemcitabine